You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Amyloid-β (Aβ) aggregation inhibitor; blocks Aβ(1-42) aggregation and protects neuronal cell lines exposed to Aβ(1-42). Reduces Aβ oligomer-induced LTP and memory deficits in vivo.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Scopes et al (2012) Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity. Br.J.Pharmacol. 167 383 PMID: 22913627
View Related Products by Target
View Related Products by Product Action
Keywords: SEN 1269, SEN 1269 supplier, SEN1269, Amyloid-β, (Aβ), aggregation, inhibitors, inhibits, LTP, memory, Alzheimer's, amyloidbeta, amyloidb, Amyloid, Beta, Peptides, 4699, Tocris Bioscience
Citations for SEN 1269
Citations are publications that use Tocris products.
Currently there are no citations for SEN 1269.
Reviews for SEN 1269
There are currently no reviews for this product. Be the first to review SEN 1269 and earn rewards!
Have you used SEN 1269?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.